Andere talen Lyell Immunopharma, Inc.

Aandelen

LYEL

US55083R1041

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,17 ^USD	-3,56%		-11,07%	+11,86%

28/02	Lyell Immunopharma, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
28/02	Lyell Immunopharma, Inc. rapporteert winstresultaten voor het vierde kwartaal dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting	05/03
North American Morning Briefing : Stock Futures -2-	04/03
Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Reports Q4 Revenue $13,000	28/02
Lyell Immunopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023	28/02
Lyell Immunopharma Announces Participation in March Investor Conferences	26/02
Lyell Immunopharma Announces Participation in March Investor Conferences	26/02
Phoenix Biotech Acquisition Corp. completed the acquisition of CERo Therapeutics, Inc.	14/02
MaxCyte's strategic platform licences redeem otherwise modest results	09/01
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference	03/01
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) dropped from S&P Biotechnology Select Industry Index	18/12
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma	09/11
Lyell Immunopharma: Q3 Earnings Snapshot	07/11
Earnings Flash (LYEL) LYELL IMMUNOPHARMA Posts Q3 Revenue $25,000	07/11
Lyell Immunopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023	07/11
SITC 2023: Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors	04/11
SITC 2023: Epi-R P2 protocol produces a scalable polyclonal TIL product with a greater expansion success rate across hot and cold tumors in shorter culture time	03/11
SITC 2023: Rejuvenation of tumor-infiltrating lymphocytes (TIL) through Partial Reprogramming	03/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Lyell Immunopharma, Inc.

Aandelen

LYEL

US55083R1041

Andere talen

Filters